logo
  

Oshkosh Reinstates FY21 Outlook Above Estimates; Declares Dividend - Quick Facts

While reporting financial results for the second quarter on Wednesday, Oshkosh Corp. (OSK) reinstated its earnings, adjusted earnings and net sales guidance for the full-year 2021, and also declared a quarterly cash dividend.

For fiscal 2021, the company now projects earnings in a range of $6.10 to $6.60 per share and adjusted earnings in a range of $6.35 to $6.85 per share on projected net sales between $7.75 billion and $7.95 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.83 per share on net sales of $7.24 billion for the year. Analysts' estimates typically exclude special items.

Further, the Company's Board of Directors today declared a quarterly cash dividend of $0.33 per share of Common Stock, payable on May 28, 2021, to shareholders of record as of May 14, 2021.

"We expect our strong second quarter performance and improved outlook to yield growth in revenues, operating income and earnings per share in fiscal 2021 compared with last year's results," said John Pfeifer, president and CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT